32 results
8-K
EX-99.1
ANNX
Annexon Inc
7 Jun 24
Annexon Announces Pricing of $125 Million Underwritten Public Offering
4:42pm
. Annexon’s novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its
8-K
EX-99.1
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Annexon’s novel scientific approach targets upstream C1q to block
8-K
EX-99.2
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
Trial Targets downstream complement (C5) Blocks entire classical complement MOA ‐ misses important upstream cascade complement drivers of nerve … Directly targets mechanism driving extensive nerve damage and paralysis Complement is an established target in GBS C1q binds to autoantibodies on nerve
8-K
EX-99.1
ANNX
Annexon Inc
13 May 24
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
4:05pm
scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates
8-K
EX-99.1
ANNX
Annexon Inc
7 May 24
Other Events
4:05pm
scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates
8-K
EX-99.1
xt16y m5m
26 Mar 24
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
4:05pm
8-K
EX-99.1
qfobz3rb
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K
EX-99.1
ayp9tj4km2g6
8 Jan 24
Regulation FD Disclosure
4:09pm
8-K
EX-99.2
0pl0a5guuyht 14oq
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
tiu4wmtx
20 Dec 23
Regulation FD Disclosure
5:17pm
424B3
c28tw1yqtc9
16 Nov 22
Prospectus supplement
4:26pm
S-3
u06kugia
4 Nov 22
Shelf registration
4:47pm
8-K
EX-99.1
sghjwrwvy
7 Jun 22
Other Events
4:06pm
8-K
EX-99.1
vdqh cu7v
9 May 22
Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results
4:20pm
8-K
EX-99.1
eaiegr oybvr
11 Jan 21
Regulation FD Disclosure
6:06am
S-8
EX-99.2
ody6mc bsli
24 Jul 20
Registration of securities for employees
5:31pm